CSIMarket
Company Name or Ticker Symbol
Search for other Categories
 


Stemline Therapeutics Inc  (STML)
Other Ticker:  
 
 

STML's Income from Cont. Operations Growth by Quarter and Year

Stemline Therapeutics Inc's Income from Cont. Operations results by quarter and year




STML Income from Cont. Operations (in millions $) FY 2018 FY 2017 FY 2016 FY 2015
IV Quarter December - -16.06 -9.92 -9.23
III Quarter September -21.04 -15.46 -9.32 -10.15
II Quarter June -18.42 -14.57 -9.05 -7.68
I Quarter March -21.75 -10.01 -10.18 -6.93
FY   -61.21 -56.10 -38.47 -33.99



STML Income from Cont. Operations third quarter 2018 Y/Y Growth Comment
Stemline Therapeutics Inc in the third quarter recorded loss from continued operations of $ -21.04 millions.

According to the results reported in the third quarter, Stemline Therapeutics Inc achieved the best Income from Cont. Operations growth in Major Pharmaceutical Preparations industry. While Stemline Therapeutics Inc' s Income from Cont. Operations no change of % ranks overall at the positon no. in the third quarter.




STML Income from Cont. Operations ( Y/Y Growth %) 2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Stemline Therapeutics Inc's third quarter 2018 Income from Cont. Operations $ 0.00 millions STML's Income Statement
Stemline Therapeutics Inc's third quarter 2017 Income from Cont. Operations $ 0.00 millions Quarterly STML's Income Statement
New: More STML's historic Income from Cont. Operations Growth >>


STML Income from Cont. Operations (Quarter on Quarter Growth %)

2018
2017 2016 2015
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Income from Cont. Operations third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Income from Cont. Operations third quarter 2018 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Income from Cont. Operations by Quarter for the Fiscal Years 2015, 2016, 2017, 2018

Stemline Therapeutics Inc's Q/Q Income from Cont. Operations Growth


Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


STML's III. Quarter Q/Q Income from Cont. Operations Comment
Recent loss from continued operations of -21.04 millions by Stemline Therapeutics Inc appear even less good compare to the -18.42 millions loss from continued operations in the second quarter.

Within Major Pharmaceutical Preparations industry Stemline Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Stemline Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Income from Cont. Operations Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


STML's III. Quarter Q/Q Income from Cont. Operations Comment
Current results of -21.04 millions by Stemline Therapeutics Inc appear even worse if you take a look at -18.42 millions in the second quarter.

Within Major Pharmaceutical Preparations industry Stemline Therapeutics Inc achieved highest sequential Income from Cont. Operations growth. While Stemline Therapeutics Inc's Income from Cont. Operations growth quarter on quarter, overall rank is .


Stemline Therapeutics Inc's 12 Months Income from Cont. Operations Growth Year on Year


Income from Cont. Operations TTM Growth

12 Months Ending
(Sep 30 2018)
12 Months Ending
(Mar 31 2018)
12 Months Ending
(Dec 31 2017)
12 Months Ending
(Sep 30 2017)
12 Months Ending
(Jun 30 2017)
Cumulative Income from Cont. Operations 12 Months Ending $ -77.27 $ -71.68 $ -67.83 $ -56.09 $ -49.96
Y / Y Income from Cont. Operations Growth (TTM) - - - - -
Year on Year Income from Cont. Operations Growth Overall Ranking # # # # #
Seqeuential Income from Cont. Operations Change (TTM) - - - - -
Seq. Income from Cont. Operations Growth (TTM) Overall Ranking # # # # #




Cumulative Income from Cont. Operations growth Comment
Stemline Therapeutics Inc' has realized cumulative trailing twelve months loss from continued operations of $ -77 millions in the Sep 30 2018 period.
The situation is getting worse as the cumulative loss from continued operations is becoming larger from $ -71.68 millions in TTM ending quarter Mar 31 2018 and $ -18.42 millions for the twelve months ending in the quarter Jun 30 2017 Sigrid Hansson wrote.

Stemline Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Income from Cont. Operations growth Comment
Stemline Therapeutics Inc' has realized cumulative trailing twelve months loss from continued operations of $ -77 millions in the Sep 30 2018 period.
The results are worsening as the cumulative loss from continued operations is becoming larger from $ -71.68 millions for the period from Mar 31 2018 to Jun 30 2017 and $ -18.42 millions for the twelve months ending in the quarter Jun 30 2017.

Stemline Therapeutics Inc achieved highest trailing twelve month year on year Income from Cont. Operations growth. While overall Income from Cont. Operations growth ranking, remained unchanged compare to the previous quarter at no. .

Income from Cont. Operations TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Income from Cont. Operations TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Income from Cont. Operations TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Income from Cont. Operations Growth
Major Pharmaceutical Preparations Industry Income from Cont. Operations Growth Trends and Statistics
Healthcare Sector Income from Cont. Operations Growth Statistics
Income from Cont. Operations Growth Trends for overall market
STML's Income from Cont. Operations Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Income from Cont. Operations Growth
Lowest Ranking Income from Cont. Operations Growth
Income from Cont. Operations Growth for STML's Competitors
Income from Cont. Operations Growth for Stemline Therapeutics Inc's Suppliers
Income from Cont. Operations Growth for STML's Customers

You may also want to know
STML's Annual Growth Rates STML's Profitability Ratios STML's Asset Turnover Ratio STML's Dividend Growth
STML's Roe STML's Valuation Ratios STML's Financial Strength Ratios STML's Dividend Payout Ratio
STML's Roa STML's Inventory Turnover Ratio STML's Growth Rates STML's Dividend Comparisons



Companies with similar Income from Cont. Operations no change for the quarter ending Sep 30 2018 within Healthcare SectorY/Y Change %Income from Cont. Operations for the quarter ending Sep 30 2018
Icu Medical Inc  61.03 %$ 61.029 millions
Dynatronics Corp  58.88 %$ 58.875 millions
Exelixis, Inc.  55.60 %$ 55.600 millions
Cambrex Corp  55.22 %$ 55.215 millions
Regeneron Pharmaceuticals Inc  53.14 %$ 53.136 millions
Boston Scientific Corporation  52.65 %$ 52.650 millions
Radnet, Inc.  49.99 %$ 49.987 millions
Masimo Corp  45.60 %$ 45.600 millions
Repro Med Systems Inc  45.46 %$ 45.455 millions
Chemed Corp  44.62 %$ 44.620 millions
Orasure Technologies Inc  40.48 %$ 40.482 millions
Stryker Corp  35.94 %$ 35.945 millions
Tabula Rasa Healthcare, Inc.  35.36 %$ 35.361 millions
Edwards Lifesciences Corp  32.80 %$ 32.804 millions
Idexx Laboratories Inc  32.19 %$ 32.192 millions
Tactile Systems Technology Inc  30.10 %$ 30.104 millions
Pacific Health Care Organization Inc  29.99 %$ 29.987 millions
Quest Diagnostics Inc  29.71 %$ 29.714 millions
Corcept Therapeutics Inc  29.00 %$ 29.003 millions
Encompass Health Corp  28.40 %$ 28.404 millions
Electromed, Inc.  27.47 %$ 27.470 millions
Alpha Pro Tech Ltd  26.87 %$ 26.873 millions
Staar Surgical Co  24.38 %$ 24.382 millions
Tenax Therapeutics, Inc.  24.03 %$ 24.033 millions
Pdl Biopharma, Inc.  23.27 %$ 23.268 millions
Resmed Inc  22.77 %$ 22.772 millions
Petmed Express Inc  22.74 %$ 22.740 millions
Align Technology Inc  22.19 %$ 22.188 millions
Mettler Toledo International Inc  20.68 %$ 20.679 millions
Universal Health Services Inc  20.31 %$ 20.307 millions


     
       
Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

SPWH's Profile

Stock Price

SPWH's Financials

Business Description

Fundamentals

Charts & Quotes

SPWH's News

Suppliers

SPWH's Competitors

Customers & Markets

Economic Indicators

SPWH's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Expectations

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.  Free Stock Market News Feeds
   Copyright © 2018 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday Data provided by Barchart and subject to terms of use. To view Intraday Stock Data Java must be installed. Java content may be prohibited by the security software, to see the stock quotes, choose "allow content from this page" option. Stock Price, historical and current end-of-day data provided by eoddata. Intraday data delayed per exchange requirements. S&P/Dow Jones Indices (SM) from Barchart and Eoddata. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071